THL Credit TCRX 深 沪
已收盘 12-12 16:00:00 美东时间
1.01
-0.060
-5.61%
华盛通- 最 高1.075
- 今 开1.06
- 成交量 36.41万股
- 最 低 1.01
- 昨 收 1.07
- 总市值 5731.55万
- 52周最高 3.43
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.91
- 委 比 74.84%
- 总股本 5674.80万
- 历史最高 14.71
- 量 比 0.43
- 振 幅 6.07%
- 历史最低 0.91
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia ...
12-05 01:20
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.
11-13 20:53
TScan Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate, Sales $2.511M Beat $1.980M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 5.41 percent. This is a 12 percent decrease over losses of $(0.25) per share from
11-12 20:13
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
BTIG Downgrades TScan Therapeutics to Neutral
BTIG analyst Justin Zelin downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral.
11-04 19:23
TScan Therapeutics shares are trading lower. The company announced regulatory and clinical program updates, implementation of a workforce reduction of approximately 30%, and extension of its cash runway into the second half of 2027.
TScan Therapeutics shares are trading lower. The company announced regulatory a...
11-03 22:22
TScan Therapeutics To Present New Research On T Cell Therapies At ACR Convergence 2025 In Chicago
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today
09-17 19:03
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
<p>TScan Therapeutics announced the acceptance of two abstracts for presentation at the ACR Convergence 2025, highlighting novel T cell targets in autoimmune disorders like Ankylosing Spondylitis using their TargetScan technology. The findings aim to advance therapies for these conditions.</p>
09-17 11:00
TScan Therapeutics to Participate in Upcoming Investor Conferences
<p>TScan Therapeutics announced participation in upcoming investor conferences: the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 9 and the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 10. Webcasts will be available on the company's website, ir.tscan.com, with replays accessible for 90 days. TScan focuses on developing TCR-engineered T cell therapies for cancer treatment.</p><br>
09-03 11:00
